Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus

robot
Abstract generation in progress

Exact Sciences shareholders have approved the acquisition by Abbott Laboratories, moving the deal closer to completion. The approval highlights investor support for the merger of the two healthcare companies and Exact Sciences’ focus on cancer screening diagnostics. Investors will now monitor regulatory reviews and integration plans, with the stock trading near analyst targets but still considered undervalued by Simply Wall St’s model.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin